健康管理顾问

Chinese cell therapy group established in 2022 in Shenzhen, Guangdong with fifty-five million yuan of registered capital and Bai Zongke as legal representative, recognised as a national high-tech enterprise in January 2025. Runs a full chain platform combining a cell therapy research institute, a science and technology innovation centre led by top scientists including a Nobel laureate, a testing laboratory, outpatient clinics and what it describes as the largest cell cryopreservation bank in the Guangdong-Hong Kong-Macao Greater Bay Area, which it is building in the Dapeng district of Shenzhen. Works to advance cell therapy and to provide innovative approaches in cancer prevention and treatment, and supplies primary cell products.